SEC Company Response from Entera Bio Ltd. (ENTX, ENTXW) (CIK 0001638097) (ENTX) — Jan 29, 2018

Entera Bio Ltd. (ENTX, ENTXW) (CIK 0001638097)
Date: Jan. 29, 2018 · CIK: 0001638097 · Accession: 0000950103-18-000931

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-221472

Date

January 29, 2018

Author

ENTERA BIO LTD.

Form

CORRESP

Company

Entera Bio Ltd. (ENTX, ENTXW) (CIK 0001638097)

Letter

Division of Corporation Finance Ms. Mary B. Breslin Re: Entera Bio Ltd. Registration Statement on Form F-1 Registration No. 333-221472

Dear Ms. Sarmento and Ms. Breslin,

Reference is made to our letter, filed as correspondence via EDGAR on January 19, 2018, in which we requested the acceleration of the effective date of the above-referenced registration statement for Tuesday, January 23, 2018, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

[Signature Page Follows]

Sincerely,
ENTERA BIO LTD.

Show Raw Text

CORRESP
1
filename1.htm

        Entera Bio Ltd.

        Kiryat Hadassah

        Minrav Building – Fifth
Floor

        Jerusalem 9112002

        Israel

        January 29, 2018

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-3628

 Attn: Ms. Ada D. Sarmento

Ms. Mary B. Breslin

    Re:
    Entera Bio Ltd.

Registration Statement on Form F-1

Registration No. 333-221472

Dear Ms. Sarmento and Ms. Breslin,

Reference is made to our letter, filed as correspondence via
EDGAR on January 19, 2018, in which we requested the acceleration of the effective date of the above-referenced registration statement
for Tuesday, January 23, 2018, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended.
We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw
our request for acceleration of the effective date.

[Signature Page Follows]

Sincerely,

    ENTERA BIO LTD.

    By:
    /s/ Phillip Schwartz

    Name:	Phillip Schwartz

    Title:	Chief Executive Officer

Via EDGAR

CC: 	Michael Kaplan, Davis Polk & Wardwell LLP

Sophia Hudson, Davis Polk & Wardwell
LLP

SecProbe.io